文献类型：期刊文献

英文题名：Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells

作者：Lei, Zi-Ning[1];Teng, Qiu-Xu[1];Wu, Zhuo-Xun[1];Ping, Feng-Feng[2];Song, Peng[3];Wurpel, John N. D.[1];Chen, Zhe-Sheng[1]

第一作者：Lei, Zi-Ning

通信作者：Wurpel, JND[1];Chen, ZS[1]

机构：[1]St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, New York, NY USA;[2]Nanjing Med Univ, Dept Reprod Med, Wuxi Peoples Hosp Affiliated, Wuxi, Jiangsu, Peoples R China;[3]Gansu Univ Chinese Med, Key Lab Prevent & Treatment Chron Dis TCM Gansu P, Affiliated Hosp, Lanzhou, Peoples R China

第一机构：St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, New York, NY USA

通信机构：[1]corresponding author), St Johns Univ, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Queens, NY 11439 USA.

年份：2021

卷号：2

期号：4

起止页码：765

外文期刊名：MEDCOMM

收录：Scopus(收录号：2-s2.0-85126363324);WOS:【ESCI(收录号:WOS:000730535200001)】；

基金：Department of Pharmaceutical Sciences, St. John'sUniversity; WuxiTaihu LakeTalent PlanTopTalents Project, Grant/Award Number: BJ 2020001

语种：英文

外文关键词：ABCB1; colorectal cancer; CRISPR; Cas9; multicellular tumor spheroids; multidrug resistance

摘要：Multidrug resistance (MDR) has been extensively reported in colorectal cancer patients, which remains a major cause of chemotherapy failure. One of the critical mechanisms of MDR in colorectal cancer is the reduced intracellular drug level led by the upregulated expression of the ATP-binding cassette (ABC) transporters, particularly, ABCB1/P-gp. In this study, the CRISPR/Cas9 system was utilized to target ABCB1 in MDR colorectal cancer SW620/Ad300 cell line with ABCB1 overexpression. The results showed that stable knockout of ABCB1 gene by the CRISPR/Cas9 system was achieved in the MDR cancer cells. Reversal of MDR against ABCB1 chemotherapeutic drugs increased intracellular accumulation of [H-3]-paclitaxel accumulation, and decreased drug efflux activity was observed in MDR SW620/Ad300 cells after ABCB1 gene knockout. Further tests using the 3D multicellular tumor spheroid model suggested that deficiency in ABCB1 restrained tumor spheroid growth and restore sensitivity to paclitaxel in MDR tumor spheroids. Overall, the CRISPR/Cas9 system targeting the ABCB1 gene can be an effective approach to overcome ABCB1-mediated MDR in colorectal cancer SW620/Ad300 cells.